GREEN ANDREW M sold $287K of AORT

Artivion (AORT) reported 9% revenue growth and 8% adjusted EBITDA decline in Q3 2026. The company projects 2026 revenue between $484M and $492M, with the NEXUS launch planned for January 2027.

Artivion, Inc. (AORT) reported a Q3 loss of $7.9 million, down from a profit last year. Adjusted EPS was 8 cents. Revenue was $123.8 million. The company expects Q4 revenue between $484M and $492M. Shares have fallen 45% YTD and 46% over 12 months.

ARTIVION, INC. (AORT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston Executive Vice President, Phone: 332-895-3222 Chief Operating Officer & investors@artivion.com Chief Financial Officer Phone: 770-419-3355 Artivion Reports Third Quarter 2026 F

Artivion reported Q3 2026 revenue of $123.8M, up 9% YoY, with a net loss of $7.9M. Adjusted EBITDA declined 8% to $22.5M. CEO Pat Mackin highlighted growth in On-X and stent grafts, and progress in product launches. The company narrowed its 2026 revenue outlook to $484M-$492M, with adjusted EBITDA expected between $93M-$98M.

Artivion (AORT) stock rose 4.7% after Jefferies initiated coverage with a Buy rating and $31 price target, citing near-term product catalysts and growth potential. The firm expects 39% upside from the prior close, highlighting product launches and margin accretion. Artivion's Q3 2026 earnings report is due soon, adding to near-term interest.

Artivion Inc (NYSE:AORT) shares rose 4.2% after Jefferies initiated coverage with a Buy rating and $31 price target. The firm cited the company's expanding product pipeline, expected double-digit revenue growth, and expanding profit margins. Jefferies forecasts $547M and $617M in revenue for 2027 and 2028, respectively, above consensus. The stock is seen as undervalued relative to peers, offering an attractive entry point ahead of commercial catalysts.